GenSight Biologics
113 articles about GenSight Biologics
-
GenSight Biologics Reports Second Patient Case Showing Significant Visual Recovery after GS030 Optogenetic Treatment
11/17/2021
GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, reported a second case of a patient with late-stage retinitis pigmentosa who partially recovered her visual function after treatment with GS030 optogenetic therapy.
-
GenSight Biologics to Present New Clinical Data of LUMEVOQ® and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting
11/12/2021
GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that clinical data of LUMEVOQ® and GS030 gene therapies will be presented at the 125th Annual Meeting of the American Academy of Ophthalmology in New Orleans, Louisiana.
-
GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa
10/12/2021
GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that the U.S. Food & Drug Administration has granted Fast Track Designation to GS030, which combines AAV2-based gene therapy with optogenetics to treat Retinitis Pigmentosa.
-
GenSight Biologics Announces the Publication of a Review of Gene Therapy Trials for LHON in International Ophthalmology Clinics
10/6/2021
GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that the peer-reviewed journal International Ophthalmology Clinics has published a review of current and past gene therapy clinical trials for the treatment of Leber hereditary optic neuropathy.
-
GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa
9/15/2021
GenSight Biologics announced that the independent Data Safety Monitoring Board completed its third safety review of the ongoing PIONEER Phase I/II clinical trial of GS030 combining AAV2-based gene therapy with optogenetics for the treatment of Retinitis Pigmentosa.
-
GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III Trials
9/9/2021
GenSight Biologics announced that the Journal of Neuro-Ophthalmology has published a paper on a cross-sectional analysis of the baseline characteristics of the ND4-LHON subjects enrolled in the RESCUE and REVERSE Phase III trials of LUMEVOQ®.
-
UK MHRA Grants GenSight Biologics’ LUMEVOQ® Ophthalmic Gene Therapy Promising Innovative Medicine Designation
9/6/2021
GenSight Biologics announced that its gene therapy LUMEVOQ® has been granted Promising Innovative Medicine designation by the UK’s Medicines and Healthcare products Regulatory Agency for the treatment of vision loss due to Leber Hereditary Optic Neuropathy caused by a confirmed G11778A mutation in the ND4 mitochondrial gene.
-
GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ®
8/31/2021
GenSight Biologics announced that the Journal of Neuro-Ophthalmology has published results from RESTORE, the long-term follow-up study of LUMEVOQ®, which show sustained treatment effect from a unilateral injection of LUMEVOQ® three years after injection in the RESCUE and REVERSE trials.
-
GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France
7/5/2021
GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that the French Competent Authority, the National Agency for Medicines and Health Products Safety, granted a Cohort Temporary Authorization for Use for LUMEVOQ® in the treatment of Leber Hereditary Optic Neuropathy caused by a mutated ND4 gene.
-
GenSight Biologics Reports Topline Results from REFLECT Phase III Clinical Trial, Confirming LUMEVOQ® Efficacy Including Better Efficacy with Bilateral Treatment
6/30/2021
GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, reported key efficacy and safety findings at 1.5 years post-treatment in the REFLECT Phase III clinical trial for LUMEVOQ®.
-
GenSight Biologics Appoints Marion Ghibaudo as Chief Technical Officer to Lead GS030 Device Engineering
6/10/2021
GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced the appointment of Marion Ghibaudo as Chief Technical Officer.
-
GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ® versus Natural History in Frontiers in Neurology
6/1/2021
GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ ® versus Natural History in Frontiers in Neurology Clinically meaningful difference between visual outcomes of LUMEVOQ ® -treated patients and untreated patients
-
GenSight Biologics to Host a Key Opinion Leader Webinar on the Nature Medicine Case Report: Visual Recovery after GS030 Optogenetic Treatment
5/31/2021
GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will host a Key Opinion Leader call on June 4, 2021 from 8:00 am to 9:00 am EDT.
-
Gene therapy is still very much cutting-edge with the potential to cure incurable genetic diseases. Here’s some recent news in the space.
-
GenSight Biologics Appoints Country Leads for France, Germany and the UK in Preparations for LUMEVOQ® Commercial Launch
5/19/2021
GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that the Company’s country leads for three key European markets are in place.
-
GenSight Biologics Appoints Françoise de Craecker to its Board of Directors
5/17/2021
GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced the appointment of Françoise de Craecker to its Board of Directors, replacing Natalie Mount.
-
GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye
5/3/2021
GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye Confirms that untreated ND4 LHON patients have the worst visual outcomes The natural history of ND4 LHON disease is characterized by severe and permanent deterioration of BCVA
-
GenSight Biologics Reports Cash Position as of March 31, 2021 and Provides Operational Update
4/20/2021
GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, reported its cash position as of March 31, 2021, and provided an operational update.
-
GenSight Biologics Reports Full Year 2020 Financial Results and provides an Outlook on 2021
3/10/2021
GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, reported its full year 2020 financial results and provided an outlook on 2021.